Elicio Therapeutics, Inc. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-12-06

Reporting Person: Goldberg Itzhak (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-06	Common Stock	S	32118	$3.3539	Disposed	1720068	Direct

Footnotes

F1: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.45 inclusive.